Pharmaceutical composition containing gp34 binding-inhibitory agent as effective ingredient
CA 2272605 A1 · Owner: Murata, Kazuko · Inventors: Higashimura, Norikazu; Sugamura, Kazuo; Murata, Kazuko
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A medicinal composition containing a gp34 binding inhibitor as the active ingredient for treating autoimmune diseases including rheumatism multiple , sclerosis, sarcoidosis, autoimmune ophthalmic diseases and inflammatory bowel disease or graft-versus-host disease. It has been experimentally confirmed that the onset of pathological conditions in rheumatism models and multiple sclerosis models can be inhibited by administering an antimouse gp34 rat monoclonal antibody to model mice for inducing collagen arthritis and those for inducing experimental autoimmune encephalomyelitis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 24, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 24, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 24, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.